Floatz logo

19 assets in Acquired Polycythemia Vera

Therapeutic assets addressing Acquired Polycythemia Vera, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ruxolitinib
Acquired Polycythemia Vera
University of WashingtonP4BB (70)
Tacrolimus
Acquired Polycythemia Vera
Thomas Jefferson UniversityP2BB (68)
Fludarabine
Acquired Polycythemia Vera
Thomas Jefferson UniversityP2BB (67)
Cyclophosphamide
Acquired Polycythemia Vera
Thomas Jefferson UniversityP2BB (65)
Panobinostat
Acquired Polycythemia Vera
Novartis PharmaceuticalsP4B (61)
Carboplatin
Acquired Polycythemia Vera
National Cancer Institute (NCI)P2B (60)
Decitabine
Acquired Polycythemia Vera
University of WashingtonP2B (60)
Nogitecan
Acquired Polycythemia Vera
National Cancer Institute (NCI)P2B (60)
Veliparib
Acquired Polycythemia Vera
National Cancer Institute (NCI)P2B (60)
Azacitidine
Acquired Polycythemia Vera
M.D. Anderson Cancer CenterP1/2B (57)
Melphalan
Acquired Polycythemia Vera
Thomas Jefferson UniversityP2B (57)
Fedratinib
Acquired Polycythemia Vera
University of WashingtonP2CCC (53)
Pevonedistat
Acquired Polycythemia Vera
M.D. Anderson Cancer CenterP1/2CCC (48)
Venetoclax
Acquired Polycythemia Vera
M.D. Anderson Cancer CenterP1/2CCC (48)
Pacritinib
Acquired Polycythemia Vera
University of WashingtonP2CC (46)
Glb-001
Acquired Polycythemia Vera
Hangzhou GluBio Pharmaceutical Co., Ltd.P1CC (43)